Retrospective analysis of fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide.

被引：1
|
作者：
Sridhar, Srikala S.
Smith, Alan D.
Fallah-Rad, Nazanin
Hansen, Aaron Richard
机构：
[1] Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Princess Margaret Hosp, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.374
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
374
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis
    Klara Kvorning Ternov
    Alexander Bjørneboe Nolsøe
    Ola Bratt
    Mikkel Fode
    Henriette Lindberg
    Caroline Kistorp
    Ganesh Palapattu
    Tobias Wirenfeldt Klausen
    Jens Sønksen
    Peter Busch Østergren
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 948 - 961
  • [32] Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis
    Ternov, Klara Kvorning
    Nolsoe, Alexander Bjorneboe
    Bratt, Ola
    Fode, Mikkel
    Lindberg, Henriette
    Kistorp, Caroline
    Palapattu, Ganesh
    Klausen, Tobias Wirenfeldt
    Sonksen, Jens
    ostergren, Peter Busch
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 948 - 961
  • [33] PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival
    K. Rahbar
    M. Boegemann
    A. Yordanova
    M. Eveslage
    M. Schäfers
    M. Essler
    H. Ahmadzadehfar
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 12 - 19
  • [34] Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
    Morris, Michael J.
    Rathkopf, Dana E.
    Novotny, William
    Gibbons, Jacqueline A.
    Peterson, Amy C.
    Khondker, Zakaria
    Ouatas, Taoufik
    Scher, Howard I.
    Fleming, Mark T.
    CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3774 - 3781
  • [35] Prognostic Factors in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide (ENZA) Or Bicalutamide (BIC) in Terrain
    Corcoran, N. M.
    Heidenreich, A.
    Shore, N.
    Villers, A.
    Klotz, L.
    Siemens, D. R.
    van Os, S.
    Baron, B.
    Wang, F.
    Chowdhury, S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 57 - 57
  • [36] PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival
    Rahbar, K.
    Boegemann, M.
    Yordanova, A.
    Eveslage, M.
    Schaefers, M.
    Essler, M.
    Ahmadzadehfar, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (01) : 12 - 19
  • [37] Effects of abiraterone in Japanese men with metastatic castration-resistant prostate cancer after enzalutamide treatment
    Iio, Hiroyuki
    Shiozaki, Keito
    Ozaki, Kisuke
    Tsujioka, Takuya
    Nishimura, Kennichi
    Fujikata, Shirou
    Tanimoto, Shuuji
    Okamoto, Kenjirou
    Yamashi, Sadamu
    Kan, Masaharu
    ANNALS OF ONCOLOGY, 2016, 27
  • [38] Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure The UPWARD Study
    Slovin, Susan
    Clark, William
    Carles, Joan
    Krivoshik, Andrew
    Park, Jung Wook
    Wang, Fong
    George, Daniel
    JAMA ONCOLOGY, 2018, 4 (05) : 702 - 706
  • [39] Low dose enzalutamide in metastatic castration-resistant prostate cancer: A retrospective Caribbean study.
    Vinh-Hung, Vincent
    Diakite, Kadiatou
    Joachim, Clarisse
    Bougas, Stefanos
    Furtos, Cristina Ioana
    Rakotonarivo, Jean-Marc
    Lababidi, Wadah
    Papadopoulou, Eva
    Escarmant, Patrick
    Veronique-Baudin, Jacqueline
    Verschraegen, Claire F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Prognostic factors in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or bicalutamide (BIC) in TERRAIN
    Heidenreich, A.
    Shore, N.
    Villers, A.
    Klotz, L.
    Siemens, D. R.
    van Os, S.
    Baron, B.
    Wang, F.
    Chowdhury, S.
    ANNALS OF ONCOLOGY, 2016, 27
12345